Abbott

ABT

Market cap $216B

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The latest trading day saw Abbott (ABT) settling at $124.64, representing a -1.02% change from its previous close.

Dividend aristocrats get plenty of attention, but most of the time the spotlight falls on the big names like Johnson & Johnson (NYSE:JNJ), Coca-Cola (NYSE:KO), and Procter & Gamble (NYSE:PG), among others.

Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two stocks is more attractive to value investors?

Abbott Laboratories is a defensive, high-quality compounder with a premium valuation justified by recurring cash flow and strong medical device platforms. Medical Devices, especially Diabetes Care (Libre), are driving over 12% segment growth, with Diabetes Care revenues surpassing $2B and growing 17%. ABT reaffirmed 2025 organic growth guidance of 7.5%–8% and EPS of $5.12–$5.18, with consistent, low-volatility earnings growth expected through 2027.

The two properties strengthen the Company's presence in Illinois, where it currently owns and manages three other properties. LAS VEGAS, NEVADA / ACCESS Newswire / January 7, 2026 / Sentinel Net Lease (the "Company") announced today that Sentinel Opportunity Fund I, LP (the "Fund") has closed on the acquisitions of two mission-critical commercial properties leased to Abbott Laboratories and V3 Engineering.

Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?

In the latest trading session, Abbott (ABT) closed at $126.45, marking a +1.82% move from the previous day.

ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens.

Traditional food logging apps offer feedback after the fact—Libre Assist1 offers help in-the-moment to inform mealtime decisions before every bite Libre Assist1 leverages AI to predict how food choices affect glucose levels,2 provides personalized meal guidance,3 and confirms glucose impact using data from Abbott's world-leading FreeStyle Libre continuous glucose monitoring (CGM) technology4 Abbott is launching Libre Assist, available at no additional cost within the Libre app,5 during CES® 2026 ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a leading healthcare company, today unveiled Libre Assist,1 a groundbreaking feature within the Libre app5 designed to help the millions of people living with diabetes in the U.S. better understand how the foods they eat affect their glucose levels.